Caerulomycin a suppresses immunity by inhibiting T cell activity

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Singla, Arvind K ^a,c   Gurram, Rama Krishna ^a   Chauhan, Arun ^a   Khatri, Neeraj ^a   Vohra, Rakesh ^a   Jolly, Ravinder S ^b   Agrewala, Javed N ^a  

^a INSTITUTE OF MICROBIAL TECHNOLOGY   (India)

^b Department of Chemistry CSIRlnstitute of Microbial Technology   (India)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CAERULOMYCIN A; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; CALCINEURIN INHIBITOR; PYRIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG DETERMINATION; DRUG ISOLATION; DRUG POTENCY; DRUG PURIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MASS SPECTROMETRY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; T LYMPHOCYTE ACTIVATION; TOXICITY TESTING; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CELL PROLIFERATION; CHEMISTRY; CYTOLOGY; CYTOTOXICITY; DRUG EFFECTS; FERMENTATION; HUMAN; IMMUNITY; IMMUNOLOGY; ISOLATION AND PURIFICATION; JURKAT CELL LINE; LYMPHOCYTE ACTIVATION; SECRETION (PROCESS); T LYMPHOCYTE;

ANIMALS; B-LYMPHOCYTES; CALCINEURIN INHIBITORS; CELL PROLIFERATION; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; FERMENTATION; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; IMMUNITY; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-GAMMA; INTERLEUKIN-10; JURKAT CELLS; LYMPHOCYTE ACTIVATION; MICE, INBRED BALB C; MICE, INBRED C57BL; PYRIDINES; T-LYMPHOCYTES; TRANSFORMING GROWTH FACTOR BETA;

EID: 84907705962     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107051     Document Type: Article

References (43)

1. Hallo ran PF (2004) Immunosuppressive drugs for kidney transplantation. N Engl J Med 351: 2715-2729.
2. Tsai SF, Cheng GY, Shu KH, Wu MJ (2012) Trends in maintenance immunosuppressive drugs used in taiwanese kidney transplant recipients: an analysis of the national health insurance research database. Transplant Proc 44: 190-192.
3. Kahan BD (1999) Cyclosporine: a revolution in transplantation. Transplant Proc 31: 14S-15S.
4. Naesens M, Kuypers DR, Sarwal M (2009) Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 4: 481-508.
5. Gallagher MP, Kelly PJ, Jardine M, Perkovic V, Cass A, et al. (2010) Long-term cancer risk of immunosuppressive regimens after kidney transplantation. J Am Soc Nephrol 21: 852-858.
6. Hoorn EJ, Walsh SB, McCormick JA, Zietse R, Unwin BJ, et al. (2012) Pathogenesis of calcineurin inhibitor-induced hypertension. J Nephrol 25: 269 -275.
7. Schlitt HJ, Barkmann A, Boker KH, Schmidt HH, Emmanouilidis N, et al. (2001) Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. Lancet 357: 587-591.
8. Raichlin E, Khalpey Z, Kremers W, Frantz RP, Rodeheffer BJ, et al. (2007) Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients. Transplantation 84: 467M74.
9. Mourad M, Malaise J, Chaib Eddour D, De Meyer M, König J, et al. (2001) Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. Clin Chem 47: 88-94.
10. Houde VP, Brule S, Festuccia WT, Blanchard PG, Bellmann K, et al. (2010) Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue. Diabetes 59: 1338 -1348.
11. Borei JF (2002) History of the discovery of cyclosporin and of its early pharmacological development. Wien Klin Wochenschr 114: 433M37.
12. Kino T, Hatanaka H, Miyata S, Inamura N, Nishiyama M, et al. (1987) FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Andbiot (Tokyo) 40: 1256-1265.
13. Sehgal SN, Baker H, Vezina C (1975) Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot (Tokyo) 28: 727-732.
14. Singla AK, Mayilraj S, Kudo T, Krishnamurthi S, Prasad GS, et al. (2005) Actinoalloteichus spitiensis sp. nov., a novel actinobacterium isolated from a cold desert of the Indian Himalayas. Int J Syst Evol Microbiol 55: 2561-2564.
15. Gurram RK, Kujur W, Maurya SK, Agrewala JN (2014) Caerulomycin A Enhances Transforming Growth Factor-beta (TGF-beta)-Smad3 Protein Signaling by Suppressing Interferon-gamma (IFN-gamma)-Signal Transducer and Activator of Transcription 1 (STAT1) Protein Signaling to Expand Regulatory T Cells (Tregs). J Biol Chem 289: 17515-17528.
16. Singla AK, Gurram RK, Chauhan A, Khatri N, Vohra RM, et al. (2014) Caerulomycin A: a potent novel immunosuppressive agent. Transplantation 97: e57-59.
17. Miller GL (1959) Use of Dinitrosalicylic Acid Reagent for Determination of Reducing Sugar. Analytical Chemistry 31: 426-428.
18. Shindo K, Yamagishi Y, Okada Y, Kawai H (1994) Collismycins A and B, novel non-steroidal inhibitors of dexamethasone-glucocorticoid receptor binding. J Antibiot (Tokyo) 47: 1072-1074.
19. Funk A, Divekar PV (1959) Caerulomycin, a new antibiotic from Streptomyces caeruleus Baldacci. I. Production, isolation, assay, and biological properties. Can J Microbiol 5: 317-321.
20. Divekar PV, Read G, Vining EC (1967) Caerulomycin, a new antibiotic from Streptomyces caeruleus Baldacci. II. Structure. Canadian Journal of Chemistry 45: 1215.
21. Ziegler SF, Ramsdell F, Alderson MR (1994) The activation antigen CD69. Stem Cells 12: 456M65.
22. Ortiz AM, Garcia-Vicuna R, Sancho D, Laffon A, Sanchez-Madrid F, et al. (2000) Cyclosporin A inhibits CD69 expression induced on synovial fluid and peripheral blood lymphocytes by interleukin 15. J Rheumatol 27: 2329-2338.
23. Tang Q, Bluestone JA (2013) Regulatory T-cell therapy in transplantation: moving to the clinic. Cold Spring Harb Perspect Med 3.
24. Weatherly K, Braun MY (2011) Organ transplantation: modulation of T-cell activation pathways initiated by cell surface receptors to suppress graft rejection. Methods Mol Biol 677: 419M30.
25. LiuJ, Farmer JD Jr, Lane WS, Friedman J, Weissman I, et al. (1991) Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 66: 807-815.
26. Manivasagan P, Venkatesan J, Sivakumar K, Kim SK (2014) Pharmaceutically active secondary metabolites of marine actinobacteria. Microbiol Res 169: 262 -278.
27. Gould DS, Auchincloss H Jr (1999) Direct and indirect recognition: the role of MHC antigens in graft rejection. Immunol Today 20: 77-82.
28. Jiang H, Chess L (2006) Regulation of immune responses by T cells. N Engl J Med 354: 1166-1176.
29. Abbas AK, Lohr J, Knoechel B, Nagabhushanam V (2004) T cell tolerance and autoimmunity. Autoimmun Rev 3: 471-475.
30. Issa F, Schiopu A, Wood KJ (2010) Role of T cells in graft rejection and transplantation tolerance. Expert Rev Clin Immunol 6: 155-169.
31. Smith-Garvin JE, Koretzky GA, Jordan MS (2009) T cell activation. Annu Rev Immunol 27: 591-619.
32. Martin P, Gomez M, Lamana A, Cruz-Adalia A, Ramirez-Huesca M, et al. (2010) CD69 association with Jak3/Stat5 proteins regulates Th17 cell differentiation. Mol Cell Biol 30: 4877-4889.
33. Galvin F, Freeman GJ, Razi-Wolf Z, Benacerraf B, Nadler L, et al. (1993) Effects of cyclosporin A, FK 506, and mycalamide A on the activation of murine CD4+ T cells by the murine B7 antigen. Eur J Immunol 23: 283-286.
34. Thomson AW (1991) The immunosuppressive macrolides FK-506 and rapamycin. Immunol Lett 29: 105-111.
35. Crespo-Leiro MG (2003) Tacrolimus in heart transplantation. Transplant Proc 35: 1981-1983.
36. Abbas AK, Murphy KM, Sher A (1996) Functional diversity of helper T lymphocytes. Nature 383: 787-793.
37. Merrill JE, Kono DH, Clayton J, Ando DG, Hinton DR, et al. (1992) Inflammatory leukocytes and cytokines in the peptide-induced disease of experimental allergic encephalomyelitis in SJL and B10.PL mice. Proc Natl Acad Sci U S A 89: 574-578.
38. Khoury SJ, Hancock WW, Weiner HE (1992) Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, and prostaglandin E expression in the brain. J Exp Med 176: 1355-1364.
39. Chang JH, K̄m YJ, Han SH, Kang CY (2009) IFN-gamma-STATl signal regulates the differentiation of inducible Treg: potential role for ROS-mediated apoptosis. Eur J Immunol 39: 1241-1251.
40. Wiederrecht GJ, Sabers GJ, Brunn GJ, Martin MM, Dumont FJ, et al. (1995) Mechanism of action of rapamycin: new insights into the regulation of Gl-phase progression in eukaryotic cells. Prog Cell Cycle Res 1: 53-71.
41. Battaglia M, Stabilini A, Migliavacca B, Horejs-Hoeck J, Kaupper T, et al. (2006) Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol 177: 8338-8347.
42. Lutterotti A, Martin R (2008) Getting specific: monoclonal antibodies in multiple sclerosis. Lancet Neurol 7: 538-547.
43. Racusen EC, Colvin RB, Solez K, Mihatsch MJ, Halloran PF, et al. (2003) Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 3: 708-714.